Cellular Intelligence (formerly Somite.ai)
Category: AI in Healthcare
An AI-powered biotechnology company developing foundation models to produce human tissue for cell-based therapies at scale. Cellular Intelligence (formerly Somite.ai) was founded in 2023. The company is led by Micha Breakstone. Based in Boston, Massachusetts, USA. Team size: 10-50. Total funding raised: Over $62 million. Latest round: Strategic Investment, Undisclosed, 2025-08, led by AMD Ventures. Key investors include Khosla Ventures, SciFi VC, Chan Zuckerberg Initiative, Fusion Fund, Ajinomoto Group Ventures, AMD Ventures.
- Founded
- 2023
- Headquarters
- Boston, Massachusetts, USA
- Team size
- 10-50
- Total funding
- Over $62 million
Value proposition
To accelerate the development and scale the production of high-purity human cells for therapies, making them more accessible for diseases like diabetes, obesity, and muscular dystrophies.
Products and solutions
DeltaStem: An AI foundation model platform that designs and optimizes protocols for generating specific human cell types from stem cells., Capsule Platform: Proprietary microfluidics platform enabling cell-signaling analysis at 1,000x higher efficiency, testing millions of signal combinations in parallel., Universal Virtual Cell-Signaling Model: Foundation model to decode and control cell behavior.
Unique value
Somite.ai aims to be the 'OpenAI of stem cell biology' by creating a universal, AI-driven platform (DeltaStem) capable of producing any cell type for any person, rather than focusing on a single disease or cell lineage.
Target customer
Pharmaceutical companies, biotechnology firms, and research institutions developing cell-based therapies.
Industries served
Biotechnology, Healthcare, Pharmaceuticals, Regenerative Medicine
Technology advantage
Their core advantage is the use of proprietary AI foundation models to create a 'digital twin' of cell differentiation. This allows for rapid, in-silico optimization of cell production protocols, leading to higher purity and scalability compared to traditional, manual lab-based methods.
How they differentiate
Somite.ai differentiates itself by using a proprietary AI foundation model, DeltaStem, to create 'digital twins of the embryo'. This allows them to overcome limitations in current cell therapy development such as purity, scale, and cost, and to model and produce any cell type for any person.
Main competitors
Vivodyne, Metagenomi, bit.bio
Key partnerships
Khosla Ventures (Lead investor for Series A), AMD Ventures (Strategic investment to accelerate AI model development), Astellas Venture Management, Montage Ventures, Novo Nordisk (Acquired STEM-PD Parkinson's cell therapy program; Novo Nordisk took equity stake)
Notable customers
OmniaBio Inc. (collaboration for Duchenne muscular dystrophy program), Novo Nordisk (STEM-PD Parkinson's cell therapy acquisition and strategic partnership)
Major milestones
Rebranded from Somite.ai to Cellular Intelligence (Jan 2026)., Released white paper on universal virtual cell-signaling model with capsule platform scaling to 1M+ signal combinations., Raised over $62 million in total funding., Acquired STEM-PD, a Phase 2-ready Parkinson's cell therapy from Novo Nordisk (May 2026); Novo Nordisk took equity stake., Expanded into Copenhagen with a 26-person team., Appointed Nuno Mendonça as Chief Medical Officer.
Growth metrics
Not publicly available
Market positioning
Somite.ai is positioning itself as a leader in the application of AI to cell therapy, aiming to become the 'OpenAI of stem cell biology'.
Geographic focus
Primarily North America
Patents and IP
Information regarding specific patents or IP is not publicly available in the provided sources.
About Micha Breakstone
Co-founder and President of Chorus.ai (acquired for $575M), Co-founder of NeuraLight.
More AI in Healthcare companies
Official website: https://www.cellularintelligence.com/